<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00561275</url>
  </required_header>
  <id_info>
    <org_study_id>TB-454</org_study_id>
    <nct_id>NCT00561275</nct_id>
  </id_info>
  <brief_title>Safety Study of Multiple Peptide Vaccine to Esophageal Cancer</brief_title>
  <official_title>Phase 1 Study of Multiple Peptide Vaccine Therapy and GM-CSF in Treating Patients With Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japanese Foundation for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Human Genome Center, Institute of Medical Science, University of Tokyo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Japanese Foundation for Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1 study of multiple peptide vaccine therapy and GM-CSF in treating patients&#xD;
      with esophageal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LY6K (lymphocyte antigen 6 complex, locus K) was identified as a new target of tumor&#xD;
      associated antigen using cDNA microarray technologies combined with the expression profiles&#xD;
      of normal and cancer tissues. On the other hand, anti-angiogenic therapy is now considered to&#xD;
      be one of promising approaches to treat of cancer. In this clinical trial, we evaluate the&#xD;
      safety and immune responses of multiple peptide cocktail including LY6K and vascular&#xD;
      endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial growth factor receptor&#xD;
      2 (VEGFR2) together with IFA and GM-CSF as immunoadjuvants in patients who had LY6K expressed&#xD;
      primary esophageal cancer. Toxicity profiles will be monitored, and antigen specific T cell&#xD;
      responses will be described.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity of multiple peptide vaccinations</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune responses including LY6K, VEGFR1 and VEGFR2 specific T cells</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">6</enrollment>
  <condition>Esophageal Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LY6K, VEGFR1, VEGFR2</intervention_name>
    <description>1 mg/body every two week with GM-CSF, 4 cycles</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have metastatic disease of esophageal cancer, and treatment has failed,&#xD;
             or in the situation where effective therapy is not available, or has been refused due&#xD;
             to severe adverse effects of chemotherapy&#xD;
&#xD;
          2. WHO performance status of 0 to 2&#xD;
&#xD;
          3. Age ≥ 20 years, ≤75 years&#xD;
&#xD;
          4. Chemotherapy, any type of radiation therapy, or immunotherapy within 4 weeks before&#xD;
             study entry&#xD;
&#xD;
          5. Expected survival of at least 3 months&#xD;
&#xD;
          6. WBC≥ 2,000/mm³ Platelet count ≥ 100,000/mm³ Total bilirubin ≤ 1.5 x the institutional&#xD;
             normal upper limits AST, ALT, ALP ≤ 2.5 x the institutional normal upper limits&#xD;
             Creatinine ≤ 1.5 x the institutional normal upper limits&#xD;
&#xD;
          7. Patients must be HLA-A2402&#xD;
&#xD;
          8. Primary lesion of esophageal cancer must express LY6K&#xD;
&#xD;
          9. Able and willing to give valid written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy (women of childbearing potential: Refusal or inability to use effective&#xD;
             means of contraception)&#xD;
&#xD;
          2. Breastfeeding&#xD;
&#xD;
          3. Serious infections requiring antibiotics&#xD;
&#xD;
          4. Patient with peptic ulcer disease&#xD;
&#xD;
          5. Previous history of intestinal perforation&#xD;
&#xD;
          6. bleeding disorders (INR ≥ 1.5)&#xD;
&#xD;
          7. Necessity of drug-mediated inhibition with platelet function&#xD;
&#xD;
          8. Taking antithrombogenic agents within 10 days&#xD;
&#xD;
          9. Serious hypertension&#xD;
&#xD;
         10. Previous history of arterial thrombosis or venous thrombosis&#xD;
&#xD;
         11. Other malignancy within 5 years prior to entry into the study, except for treated&#xD;
             non-melanoma skin cancer and cervical carcinoma in situ&#xD;
&#xD;
         12. Clinically significant heart disease or previous history of myocardial infarction&#xD;
             within the past 12 months&#xD;
&#xD;
         13. Concomitant treatment with steroids or immunosuppressing agent&#xD;
&#xD;
         14. Disease to the central nervous system&#xD;
&#xD;
         15. Decision of unsuitableness by principal investigator or physician-in-charge&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takuya Takayama, M.D.Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute of Japanese Foundation for Cancer Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Takuya Takayama M.D.Ph.D</name>
      <address>
        <city>Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res. 2006 Oct 1;12(19):5841-9.</citation>
    <PMID>17020992</PMID>
  </reference>
  <reference>
    <citation>Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005 Jun 1;65(11):4939-46.</citation>
    <PMID>15930316</PMID>
  </reference>
  <reference>
    <citation>Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci. 2007 Nov;98(11):1803-8.</citation>
    <PMID>17784873</PMID>
  </reference>
  <verification_date>July 2008</verification_date>
  <study_first_submitted>November 14, 2007</study_first_submitted>
  <study_first_submitted_qc>November 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 20, 2007</study_first_posted>
  <last_update_submitted>July 10, 2008</last_update_submitted>
  <last_update_submitted_qc>July 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

